Testing 527 Cancer Drugs on Mesothelioma

ByHolly Zink
Testing 527 Cancer Drugs on Mesothelioma

A new study from Finland tested over 500 cancer drugs on malignant pleural mesothelioma (MPM) cells to find new treatments for this aggressive disease.

As of this writing, the only FDA approved chemotherapy for MPM is a combination of pemetrexed and cisplatin. Even though this is the most common first-line treatment for MPM, it is not always effective at improving survival.

This is why studies that look for new drug treatments are so important. This research can help doctors to find better treatments for MPM in the future.

Worldwide Poor Prognosis

MPM is a rare cancer caused by asbestos exposure. It affects the membranes around the lungs and can spread to the lungs and elsewhere in the chest.

MPM has a rising incidence which will continue worldwide until around 2030. MPM patients often face a poor prognosis. Many have only 4 to 12 months of survival after diagnosis if untreated. Most treatments aim to improve the patient’s quality of life and prolong survival.

Standard therapies for MPM include chemotherapy, radiation, and surgery. If more than one of these therapies is used it may be called multimodal therapy.

Effective Drugs for Mesothelioma

In this study, the researchers looked at 527 cancer drugs in a lab setting. They took the 19 drugs that had the best results and ran more tests on them.

The researchers were able to find two types of drugs that had positive results in the lab. These two types of drugs are called mTOR inhibitors and Chk1 inhibitors. They work by stopping the mesothelioma cells from growing and spreading.

Now that researchers know these drugs are effective in a lab, they can do more studies on them to learn more about how they work.

Approximately 2,500 people in the US receive a mesothelioma diagnosis each year. Most of them worked in an industry that exposed them to asbestos.

Source

Ollila-Raj H, Murumägi A, Pellinen T, et al. Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing [published online ahead of print, 2023 Mar 1]. Lung Cancer. 2023;178:213-219. doi:10.1016/j.lungcan.2023.02.024. https://pubmed.ncbi.nlm.nih.gov/36878102/

Similar Posts

  • | |

    Aspirin Derivative No Match for Mesothelioma

    ByAlex Strauss

    It may work wonders for aches and pains but apparently the ‘wonder drug’ is no match for the asbestos-linked cancer, malignant mesothelioma. A number of previous studies have suggested a benefit from aspirin for some types of cancer. But Italian scientists testing the aspirin derivative [2-acetoxy-(2-propynyl) benzoate] hexacarbonyldicobalt (Co-ASS) and its analogue hexacarbonyl [μ-(2-ethylphenyl) methanol] dicobalt (Co-EPM) against malignant pleural mesothelioma cells found that both molecules function better as non-steroidal anti-inflammatory (NSAID) agents than as anti-tumor drugs. The researchers tested Co-ASS and Co-EPM against mesothelioma cells of both the more common epithelioid and rarer sarcomatoid types. The most encouraging results were seen with the sarcomatoid cells. Against this cell type, Co-ASS was found to be more potent than either Co-EPM or…

  • | |

    FDA Approval Could Mean New Choice for Mesothelioma Patients

    ByAlex Strauss

    A newly-approved drug for late-stage lung cancer may have implications for people with malignant mesothelioma, as well. The FDA recently announced its approval of afatinib, a drug which blocks epidermal growth factor receptor (EGFR) expression in cancer cells. Many types of cancer, including about half mesothelioma cases, express a specific type of mutation on the EGFR gene that causes tumors to grow even faster. Because of this, EGFR has been a focus for biomarker research in mesothelioma, as well as in a number of other cancers. In clinical trials, afatinib (brand name Gilotrif), significantly extended progression-free survival in non-small cell lung cancer patients versus the more common pemetrexed/cisplatin chemotherapy combination. Over a 12-month period, the progression-free survival of lung cancer…

  • | |

    New Drugs May Be More Effective in Mesothelioma

    ByAlex Strauss

    There is evidence that two novel mesothelioma medications may work better than some of the most commonly used drug treatments. Researchers in Stockholm, Sweden treated six mesothelioma cell lines with six different drugs, some of which are already commonly used to treat the asbestos-linked cancer.  The drugs tested include carboplatin, pemetrexed, doxorubicin and gemcitabine, all of which have been used to fight mesothelioma. The new drugs included in the tests were selenite (a form of selenium) and bortezomib (a proteasome inhibitor).  The researchers tested the drugs alone and in various combinations to see which were most effective. “As a single agent, selenite was effective on four out of six cell lines and, in combination with bortezomib, yielded the greatest response…

  • | |

    New Mesothelioma Drug Tests to Begin Soon

    ByAlex Strauss

    A spokesman for the makers of a promising new mesothelioma drug says the company plans to begin enrolling its first clinical trial participants this summer. Dr. Joanna Horobin is Chief Medical Officer for Verastem, Inc.,  the developer of a drug that aims to treat malignant mesothelioma by targeting the stem cells that give rise to it. The company’s lead compound, an oral drug called VS-6063, inhibits a crucial signaling pathway inside stem cells called the Focal Adhesion Kinase (FAK) pathway. VS-6063 was approved by the FDA earlier this year as a ‘orphan drug’, a designation given to drugs designed to treat rare illnesses like mesothelioma. “We are moving quickly to bring new treatment options to patients with mesothelioma,” Dr. Horobin said…

  • | |

    New Drug Combo May Fight Mesothelioma

    ByAlex Strauss

    A new study finds that the combination of a naturally occurring protein and a drug used to treat multiple myeloma may offer a promising new approach to treating mesothelioma. Malignant pleural mesothelioma, a cancer of the lung lining caused by asbestos exposure, is known to be difficult to treat using standard cancer therapies. The newly-tested combination of TNFalpha-Related Apoptosis Inducing Ligand (TRAIL) and the cancer drug bortezomib appears to kill mesothelioma cells by triggering “robust apoptosis” (programmed cell death). Both compounds have been studied on their own for their cancer-killing properties. The protein TRAIL is a part of the immune system secreted by most normal tissue cells. It triggers apoptosis in tumor cells by binding to what are called ‘death receptors’ in…

  • | |

    Doctors Test New Intra-Pleural Mesothelioma Drug

    ByAlex Strauss

    Doctors at Memorial Sloan Kettering Cancer Center in New York have treated the first patient in a new trial that could offer hope to people with malignant mesothelioma and one of its most common complications. The trial is a dose-escalation test of a new drug called GL-ONC1, a genetically modified vaccinia virus produced by the California biopharmaceutical company Genelux Corporation. GL-ONC1 is designed to be both therapeutic – actually treating the cancer – and diagnostic (via green fluorescent proteins) in people with mesothelioma and non-small cell lung cancer who have a buildup of lung fluid called malignant pleural effusion. In the new mesothelioma trial, which is sponsored by Memorial Sloan Kettering in collaboration with Genelux, GL-ONC1 will be administered in a single…